BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24724863)

  • 1. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial.
    Stanworth SJ; Estcourt LJ; Llewelyn CA; Murphy MF; Wood EM;
    Transfusion; 2014 Oct; 54(10):2385-93. PubMed ID: 24724863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial.
    Campbell HE; Estcourt LJ; Stokes EA; Llewelyn CA; Murphy MF; Wood EM; Stanworth SJ;
    Transfusion; 2014 Oct; 54(10):2394-403. PubMed ID: 24826894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
    Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
    Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A no-prophylaxis platelet-transfusion strategy for hematologic cancers.
    Stanworth SJ; Estcourt LJ; Powter G; Kahan BC; Dyer C; Choo L; Bakrania L; Llewelyn C; Littlewood T; Soutar R; Norfolk D; Copplestone A; Smith N; Kerr P; Jones G; Raj K; Westerman DA; Szer J; Jackson N; Bardy PG; Plews D; Lyons S; Bielby L; Wood EM; Murphy MF;
    N Engl J Med; 2013 May; 368(19):1771-80. PubMed ID: 23656642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 x 10(9) and 20 x 10(9) per L.
    Nevo S; Fuller AK; Hartley E; Borinsky ME; Vogelsang GB
    Transfusion; 2007 May; 47(5):801-12. PubMed ID: 17465944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions.
    Stanworth SJ; Dyer C; Choo L; Bakrania L; Copplestone A; Llewelyn C; Norfolk D; Powter G; Littlewood T; Wood EM; Murphy MF;
    Transfus Med Rev; 2010 Jul; 24(3):163-71. PubMed ID: 20656185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
    Wandt H; Schaefer-Eckart K; Wendelin K; Pilz B; Wilhelm M; Thalheimer M; Mahlknecht U; Ho A; Schaich M; Kramer M; Kaufmann M; Leimer L; Schwerdtfeger R; Conradi R; Dölken G; Klenner A; Hänel M; Herbst R; Junghanss C; Ehninger G;
    Lancet; 2012 Oct; 380(9850):1309-16. PubMed ID: 22877506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis.
    Stanworth SJ; Hudson CL; Estcourt LJ; Johnson RJ; Wood EM;
    Haematologica; 2015 Jun; 100(6):740-7. PubMed ID: 25795717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 x 10(9) or 20 x 10(9) per L.
    Nevo S; Fuller AK; Zahurak ML; Hartley E; Borinsky ME; Vogelsang GB
    Transfusion; 2007 Sep; 47(9):1700-9. PubMed ID: 17725737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expected individual benefit of prophylactic platelet transfusions in hemato-oncology patients based on bleeding risks.
    Cornelissen LL; Caram-Deelder C; Fustolo-Gunnink SF; Groenwold RHH; Stanworth SJ; Zwaginga JJ; van der Bom JG
    Transfusion; 2021 Sep; 61(9):2578-2587. PubMed ID: 34263930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design.
    Tinmouth A; Tannock IF; Crump M; Tomlinson G; Brandwein J; Minden M; Sutton D
    Transfusion; 2004 Dec; 44(12):1711-9. PubMed ID: 15584985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose of prophylactic platelet transfusions and prevention of hemorrhage.
    Slichter SJ; Kaufman RM; Assmann SF; McCullough J; Triulzi DJ; Strauss RG; Gernsheimer TB; Ness PM; Brecher ME; Josephson CD; Konkle BA; Woodson RD; Ortel TL; Hillyer CD; Skerrett DL; McCrae KR; Sloan SR; Uhl L; George JN; Aquino VM; Manno CS; McFarland JG; Hess JR; Leissinger C; Granger S
    N Engl J Med; 2010 Feb; 362(7):600-13. PubMed ID: 20164484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger.
    Zumberg MS; del Rosario ML; Nejame CF; Pollock BH; Garzarella L; Kao KJ; Lottenberg R; Wingard JR
    Biol Blood Marrow Transplant; 2002; 8(10):569-76. PubMed ID: 12434952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients.
    Diedrich B; Remberger M; Shanwell A; Svahn BM; Ringdén O
    Transfusion; 2005 Jul; 45(7):1064-72. PubMed ID: 15987349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies.
    Martino R; Porras RP; Rabella N; Williams JV; Rámila E; Margall N; Labeaga R; Crowe JE; Coll P; Sierra J
    Biol Blood Marrow Transplant; 2005 Oct; 11(10):781-96. PubMed ID: 16182179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New thoughts on the correct dosing of prophylactic platelet transfusions to prevent bleeding.
    Slichter SJ
    Curr Opin Hematol; 2011 Nov; 18(6):427-35. PubMed ID: 21946073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How low can you go: What is the safe threshold for platelet transfusions in patients with hematologic malignancy in sub-Saharan Africa.
    Ddungu H; Krantz EM; Kajja I; Naluzze S; Nabbanja H; Nalubwama F; Phipps W; Orem J; Kiwanuka N; Wald A
    PLoS One; 2019; 14(2):e0211648. PubMed ID: 30726290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New strategies for the optimal use of platelet transfusions.
    Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
    Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial.
    Estcourt LJ; McQuilten Z; Powter G; Dyer C; Curnow E; Wood EM; Stanworth SJ;
    Trials; 2019 Oct; 20(1):592. PubMed ID: 31615553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials.
    Christou G; Iyengar A; Shorr R; Tinmouth A; Saidenberg E; Maze D; Tay J; Bredeson C; Allan DS
    Transfusion; 2016 Oct; 56(10):2607-2614. PubMed ID: 27465524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.